Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CB-103 in advanced solid tumors and hematological malignancies
NCT03422679Phase 2Terminated
- Sponsor
- Cellestia Biotech
- Start
- Dec 2017
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of limantrafin in solid tumor, hematological malignancies, breast cancer, colorectal cancer (CRC), adenoid cystic carcinoma (ACC), sponsored by Cellestia Biotech. Started Dec 2017; status: terminated.
02
Drugs
limantrafin
03
Conditions
solid tumorhematological malignanciesbreast cancercolorectal cancer (CRC)adenoid cystic carcinoma (ACC)
Beyond the preview
Go deeper on NCT03422679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03422679.